Four things to know:
1. Of 103 total subjects, 51 were assigned to conservative management and 52 were assigned to sacroiliac joint arthrodesis between 2013 and 2015.
2. At two years, average self-rated low back pain improved by 45 points after arthrodesis and 11 points after conservative management.
3. In the group that received the iFuse implant, the prevalence of opioid use decreased from 56 percent at baseline to 33 percent at two years, while no significant change was observed in the conserved management group.
4. The triangular titanium iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis.
More articles on surface technology:
1st cases performed with Amplify Surgical’s dualX expanding interbody fusion system – 5 insights
5 things to know about a partnership to streamline 3D-printed spinal implant production
Emerging spine technologies include smart technologies, robotics & nano-engineering: Q&A with Dr. Frank Shen
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
